IN THE CLAIMS

- 1. (Currently amended) A controlled release pharmaceutical <u>tablet</u> composition of <u>Nimesulide nimesulide</u> for <u>oral peroral</u> administration which comprises a fast release <u>fraction</u> <u>layer</u> and an extended release <u>fraction layer</u> which comprises nimesulide as an active drug upto 99% w/w of the <u>tablet</u> composition, one or more release controlling materials from 0.1% to 99% w/w of the <u>tablet</u> composition and pharmaceutical excipients from 0% to 90% w/w of the <u>tablet</u> composition, said nimesulide being present in the fast release <u>fraction layer</u> and in the extended release <u>fraction layer</u>.
- 2. (Currently amended) A controlled release pharmaceutical <u>tablet</u> composition of nimesulide as claimed in claim 1 which comprises nimesulide as an active drug from 20% to 70% w/w of the <u>tablet</u> composition, one or more release controlling materials from 5% to 65% w/w of the <u>tablet</u> composition and pharmaceutical excipients from 10% to 70% w/w of the <u>tablet</u> composition.
- 3. (Cancelled)
- 4. (Currently amended) A controlled release pharmaceutical <u>tablet</u> composition of nimesulide as claimed in claim 1 wherein the release controlling materials are selected from the group consisting of cellulose and cellulose derivatives, waxes, carbomers, polyalkylene polyols, polycarbophils, methacryclic acid <u>derivatives</u> <u>copolymers</u>, gelatins, gums, and polyethylene oxides.
- (Previously presented) The composition as claimed in claim 1, which further comprises release modifiers selected from the group consisting of wetting agents, solubilizers, surfactants, plasticizers, pore formers, pH modifiers and tonicity adjusting agents.

- 6. (Currently amended) A controlled release pharmaceutical <u>tablet</u> composition as claimed in claim 1, which is a gastroretentive system wherein the residence time of the drug is increased in the stomach, duodenum, jejunum or ileum.
- 7. (Currently amended) The <u>tablet</u> composition as claimed in claim 6, wherein gastroretention of Nimesulide <u>nimesulide</u> is achieved by mucoadhesion, flotation, reducing gastrointestinal motility or a combination thereof.
- 8. (Currently amended) The <u>tablet</u> composition as claimed in claim 7, wherein mucoadhesion is achieved by treating <u>Nimesulide</u> nimesulide with polymers having affinity for gastrointestinal mucosa said polymers selected from the group consisting of polycarbophils, carbomers, alginates, cellulose and cellulose derivatives, chitosan, gums and lectins.
- 9. (Currently amended) The <u>tablet</u> composition as claimed in claim 7, wherein flotation is achieved by adding to the composition gas-generating materials selected from the group consisting of sodium bicarbonate, sodium carbonate, calcium carbonate and potassium carbonate alone or in combination with an acidic substance selected from the group consisting of hydrochloric acid, citric acid, <u>fumerie fumaric</u> acid, malic acid, maleic acid, ascorbic acid and tartaric acid.
- 10. (Currently amended) The <u>tablet</u> composition as claimed in claim 7, wherein gastrointestinal motility is reduced by <u>using</u> materials selected from the group consisting of fats, fatty acids and <u>transeterification</u> <u>transesterification</u> products of fats and fatty acids with polyols.

(Currently amended) A process for the manufacture of a controlled release <u>tablet</u> composition of <u>Nimesulide</u> nimesulide for peroral administration comprising of a fast release <u>fraction layer</u> and an extended release <u>fraction layer</u> which comprises mixing together nimesulide as an active drug up to 99% w/w of the <u>tablet</u> composition, one or more release controlling materials from 0.1% to 99% w/w of the <u>tablet</u> composition and pharmaceutical excipients from 0% to 90% w/w of the <u>tablet</u> composition said nimesulide being present in the fast release <u>fraction layer</u> and in the extended release <u>fraction layer</u>.

- (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Currently amended) The controlled release pharmaceutical <u>tablet</u> composition of nimesulide as claimed in claim 2, wherein the release controlling materials are selected from the group consisting of cellulose and cellulose derivatives, waxes, carbomers, polyalkylene [[-,-]] polyols, polycarbophils, methacrylic acid <u>derivatives</u> <u>copolymers</u>, gelatins, gums and polyethylene oxides.
- 16. (Canceled)
- 17. (Canceled)